Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Cytek Biosciences, Inc. (NASDAQ:CTKB)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Cytek Biosciences, Inc. (NASDAQ:CTKB) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 21,873 shares of the company’s stock, valued at approximately $142,000.

Other large investors have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Cytek Biosciences by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 69,074 shares of the company’s stock worth $448,000 after buying an additional 2,373 shares during the period. State of Tennessee Department of Treasury lifted its stake in shares of Cytek Biosciences by 4.4% in the 4th quarter. State of Tennessee Department of Treasury now owns 70,502 shares of the company’s stock valued at $458,000 after purchasing an additional 3,003 shares during the period. Sterling Capital Management LLC boosted its position in shares of Cytek Biosciences by 799.8% during the fourth quarter. Sterling Capital Management LLC now owns 3,887 shares of the company’s stock valued at $25,000 after purchasing an additional 3,455 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Cytek Biosciences by 0.7% during the fourth quarter. Principal Financial Group Inc. now owns 506,925 shares of the company’s stock valued at $3,290,000 after purchasing an additional 3,753 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in Cytek Biosciences in the fourth quarter worth $25,000. Institutional investors own 69.46% of the company’s stock.

Cytek Biosciences Trading Up 0.7%

NASDAQ CTKB opened at $2.85 on Wednesday. Cytek Biosciences, Inc. has a 12 month low of $2.37 and a 12 month high of $7.63. The stock’s fifty day moving average price is $3.36 and its 200-day moving average price is $4.88. The stock has a market cap of $360.98 million, a P/E ratio of -35.62 and a beta of 1.42.

Cytek Biosciences (NASDAQ:CTKB) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.05). The firm had revenue of $41.46 million for the quarter, compared to analysts’ expectations of $43.18 million. Cytek Biosciences had a negative net margin of 5.05% and a negative return on equity of 2.58%. As a group, analysts forecast that Cytek Biosciences, Inc. will post -0.06 earnings per share for the current fiscal year.

Insider Transactions at Cytek Biosciences

In other Cytek Biosciences news, CFO William D. Mccombe bought 35,000 shares of Cytek Biosciences stock in a transaction on Monday, June 2nd. The stock was acquired at an average price of $2.78 per share, with a total value of $97,300.00. Following the acquisition, the chief financial officer now owns 55,746 shares in the company, valued at approximately $154,973.88. This trade represents a 168.71% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on CTKB shares. The Goldman Sachs Group lowered their price objective on Cytek Biosciences from $3.50 to $3.00 and set a “sell” rating for the company in a research report on Monday, May 12th. Piper Sandler lowered their price target on shares of Cytek Biosciences from $8.50 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, March 4th. TD Cowen lowered shares of Cytek Biosciences from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research note on Friday, May 9th. Morgan Stanley decreased their target price on shares of Cytek Biosciences from $9.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 28th. Finally, Stephens reiterated an “overweight” rating and set a $6.00 target price on shares of Cytek Biosciences in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Cytek Biosciences presently has a consensus rating of “Hold” and an average price target of $5.60.

Cytek Biosciences Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.